What an experience! Osgoode’s team is back from their weekend of competition at the Harold G. Fox Intellectual Property Moot, and boy did we get a ‘bargain’! (more…)
Day: February 28, 2014
in Feature Post, IP Reform, Patent Practice, Patentability, Patents, Pharmaceutical Drugs0by Editor
63
China’s Bitter Medicine for Gilead: SIPO Cancels Viread Patent
Last August, China’s State Intellectual Property Office (SIPO) invalidated the core patent for Gilead Sciences‘ flagship drug Viread (as was reported by IPR Daily and a number of other news sources). This…